Lung cancer has always been considered to be a smoker’s disease. But the scenario has now changed and other factors are also contributing to it. Non-smokers are also getting trapped in the…
Sevabertinib Receive Accelerated Approval by FDA for Non-Squamous NSCLC
Lung cancer is one of the deadly disease responsible for many deaths all around the world. US Food and Drug Administration (FDA) has granted accelerated approval to Sevabertinib (Hyrnuo Bayer HealthCare Pharmaceuticals…
Stanford Mice Study Reveals Ageing Protect Against Lung Cancer
According to new research conducted at Stanford University, extreme age may provide a protective effect against lung cancer. Older laboratory mice were found to develop fewer lung tumors and those tumors were…
Lung Cancer Is No Longer Smokers’ Only Disease
Lung cancer awareness month is celebrated every year in the month of November. Smoking remains the leading cause behind lung cancer but experts are now seeing a sharp rise of lung cancer…
Lung Cancer Awareness Month: Tips to Reduce your Risk
Every year, lung cancer awareness month is observed in November to educate public about lung cancer, encourage prevention and promote its early detection. White ribbon is used to symbolize the fight against…
Role of Personalized Treatment for Lung Cancer Patients
Lung cancer is one of the most deadly disease and is responsible for many deaths each year. There are two major types of lung cancer: small cell and non-small cell lung cancer….
Toenails to Reveal Exposure to Lung Cancer Cause
Although smoking remains the root cause behind lung cancer, but it is also rising among non-smokers. The other causes include exposure to radon, second-hand smoke, explosives and more. Radon is a colorless…
Lurbinectedin Combination gets FDA Approval for Extensive-Stage SCLC
The U.S. Food and Drug Administration (FDA) has approved lurbinectedin (Zepzelca) in combination with atezolizumab or and hyaluronidase-tqjs for adults with extensive-stage small cell lung cancer (ES-SCLC) without disease progression after frontline…